INHAL 102
Alternative Names: INHAL-102Latest Information Update: 04 Sep 2023
At a glance
- Originator Inhalis Therapeutics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lung cancer